Adam Koppel and Jeff Schwartz are done raising capital. Now they have $720M to do some serious deals at Bain
When Adam Koppel looped back to Bain Capital last summer, where he had already wired himself into the healthcare finance field, he immediately paired back up with longtime partner-in-arms, Jeff Schwartz, and began to create a new life sciences fund with enough capital on hand to make a deep impact on the biotechs they would choose to back.
Today marks the official end of the fundraising period and the beginning of a 3- to 5-year stint spending all of their time investing the $720 million the two have raised; $600 million of that from external sources with the other $120 million from Bain partners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.